Evidence map›Paper›PMID 21406981›Full record

ReviewJournal of acquired immune deficiency syndromes (1999)2010

Chemoprophylaxis for HIV prevention: new opportunities and new questions.

Kenneth H Mayer, Kartik K Venkatesh

Abstract readReview
In one paragraph

Review in Journal of acquired immune deficiency syndromes (1999), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Kenneth H MayerDivision of Infectious Diseases, Department of Medicine, and Department of Community Health, Alpert Medical School, Brown University, Miriam Hospital, Providence, RI 02906, USA. Kenneth_Mayer@brown.edu
Kartik K Venkatesh

Funding

Translational ScienceP30AI042853 · NIAID · MIRIAM HOSPITAL · PI LARRY K BROWN · 1998 to 2026
$51.7M
Miriam/Brown/Tufts Fogarty AIDS International Training and Research ProgramD43TW000237 · FIC · MIRIAM HOSPITAL · PI CU-UVIN, SUSAN · 1993 to 2014
$10.6M
Optimizing Antiretroviral-Based Prevention by Enhancing PrEP Adherence in MSMR34MH095584 · NIMH · FENWAY COMMUNITY HEALTH CENTER · PI MAYER, KENNETH H · 2011 to 2013
$739k
Enhancing HIV Secondary Prevention in a clinical care setting in southern IndiaF30MH079738 · NIMH · BROWN UNIVERSITY · PI VENKATESH, KARTIK KAILAS · 2006 to 2011
$270k
FIC NIH HHS D43 TW000237FIC NIH HHS D43TW000237NIAID NIH HHS P30 AI042853NIAID NIH HHS P30 AI42853NIMH NIH HHS F30 MH079738NIMH NIH HHS F30 MH079738-01A2NIMH NIH HHS R34 MH095584
6 · The paper itself

Abstract

Growing data suggest that antiretrovirals can be used as an effective means of HIV prevention. This article reviews the current status and future clinical prospects of utilizing antiretroviral chemoprophylaxis before and after high-risk HIV exposure to prevent HIV transmission. The discussion about using antiretrovirals as a means of primary HIV prevention has moved to the forefront of public health discourse because of a growing evidence base, the increased tolerability of the medications, the decreased cost, the ever-expanding formulary, and the limitations of other approaches.

Indexed as

Anti-HIV AgentsDosage FormsDrug Administration RoutesHIV InfectionsHumansUnited StatesAnti-HIV AgentsDosage Forms

Identifiers

PMID21406981
PMCPMC3075435

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.